文献速递糖尿病

Project ECHO糖尿病试验改善医疗服务不足人群的结局

Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People.
PubMed 文献 · Diabetes Care · 2025-01-01

该研究采用阶梯楔形设计,在加利福尼亚和佛罗里达州20家联邦合格健康中心评估ECHO糖尿病项目对患者结局的影响。结果显示,干预前后HbA1c>9%的比例从31.7%降至26.7%(P=0.033),患者层面持续葡萄糖监测使用率从25.1%升至36.8%(P<0.0001),胰岛素泵使用率从15.3%升至18.3%(P<0.001)。

要点

  • 干预后HbA1c>9%的比例从31.7%降至26.7%(P=0.033)。
  • 患者持续葡萄糖监测使用率从25.1%升至36.8%(P<0.0001)。
  • 胰岛素泵使用率从15.3%升至18.3%(P<0.001)。

核心结论

  • ECHO模式在减少糖尿病健康差异方面显示出前景,并有助于理解项目在提供者层面之外的益处。

研究设计与样本

  • 采用阶梯楔形设计,在加利福尼亚和佛罗里达州招募20家联邦合格健康中心(FQHCs),随机分阶段进入干预。
  • 参与FQHCs(称为“spokes”)提供包括HEDIS和糖尿病技术使用的汇总数据;从spokes招募患者,收集历史性和前瞻性HbA1c、HEDIS标记及前后调查数据。
  • spoke层面队列包括32,796例1型糖尿病(T1D;3.4%)和2型糖尿病(T2D;96.6%)患者,其中72.7%为公共保险或无保险。
  • 患者层面队列包括582例成人糖尿病患者(33.0%为T1D,67.0%为T2D),平均年龄51.1岁,80.7%为公共保险或无保险。

主要发现

  • spoke层面,干预前后HbA1c>9%的比例从31.7%降至26.7%(P=0.033),差异有统计学意义。
  • 患者层面,干预前后持续葡萄糖监测使用率从25.1%升至36.8%(P<0.0001),差异有统计学意义。
  • 患者层面,干预前后胰岛素泵使用率从15.3%升至18.3%(P<0.001),差异有统计学意义。

关键数值与推荐

  • 使用线性混合模型生成患者层面每月HbA1c估计值并评估随时间的变化;使用泊松回归对诊所层面技术使用进行建模。
  • 患者层面队列中43.7%为非西班牙裔白人,31.6%为西班牙裔,7.9%为非西班牙裔黑人,16.8%为其他种族/族裔类别。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Project Extension for Community Healthcare Outcomes (ECHO) model is used in 180 countries to address chronic disease care through a provider empowerment, tele-education approach. Few studies have rigorously evaluated the impact of the program on patient outcomes using randomized designs. RESEARCH DESIGN AND METHODS: Implementation of an ECHO Diabetes program was evaluated using a stepped-wedge design with recruitment of 20 federally qualified health centers (FQHCs) across California and Florida with randomized, phased-in intervention entry. Participating FQHCs (referred to as "spokes") provided aggregate data, including the Healthcare Effectiveness Data and Information Set (HEDIS) and diabetes technology use. Patients were recruited from spokes, and data collection involved historical and prospective HbA1c measures, HEDIS markers, and pre/post surveys. Linear mixed models were used to generate patient-level monthly HbA1c estimates and evaluate change over time; Poisson regression was used to model clinic-level technology use. RESULTS: The spoke-level cohort included 32,796 people with type 1 diabetes (T1D; 3.4%) and type 2 diabetes (T2D; 96.6%), of whom 72.7% were publicly insured or uninsured. The patient-level cohort included 582 adults with diabetes (33.0% with T1D, 67.0% with T2D). Their mean age was 51.1 years, 80.7% were publicly insured or uninsured, 43.7% were non-Hispanic White, 31.6% were Hispanic, 7.9% were non-Hispanic Black, and 16.8% were in other race/ethnicity categories. At the spoke level, there were statistically significant reductions before and after the intervention in the proportion of people with HbA1c >9% (range 31.7% to 26.7%; P = 0.033). At the patient level, there were statistically significant increases in those using continuous glucose monitoring (range 25.1% to 36.8%; P < 0.0001) and pump use (range 15.3% to 18.3%; P < 0.001) before and after the intervention. CONCLUSIONS: The ECHO model demonstrates promise for reducing health disparities in diabetes and contributes to our understanding of program benefits beyond the provider level.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Walker AF, Haller MJ, Addala A, et al. Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People. Diabetes Care. 2025. PMID: 39688288. doi:10.2337/dc24-2100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。